OPTIMIZERx Corp. OPRX, a health care technology firm, reported on Wednesday fourth-quarter sales of $32.32 million, up 14% year-over-year, beating the consensus of $30.36 million.
OptimizeRx Corporation (NASDAQ:OPRX ) Q4 2024 Results Conference Call March 12, 2025 8:30 AM ET Company Participants Steve Silvestro - President Edward Stelmakh - Chief Financial Officer and Chief Operational Officer Andrew D'Silva - Senior Vice President of Corporate Finance Conference Call Participants Jared Haase - William Blair Anderson Schock - B. Riley Constantine Davides - Citizens JMP Richard Baldry - ROTH Capital David Grossman - Stifel Financial Eric Martinuzzi - Lake Street Jeff Garro - Stephens, Inc Operator Good morning, everyone, and thank you for joining OptimizeRx's Fourth Quarter and Full Year Fiscal 2024 Earnings Conference Call.
WALTHAM, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced results for the fourth quarter and full year ended December 31, 2024.
WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today confirmed that it has received a purported notice of nominations from a stockholder, Whetstone Capital Advisors, LLC, regarding its intention to nominate two candidates for election to the OptimizeRx Board of Directors at the Company's 2025 Annual Meeting of Stockholders.
Silvestro has a demonstrated record of accelerating revenue growth, expanding brand relevance, and building a market-leading team Silvestro has a demonstrated record of accelerating revenue growth, expanding brand relevance, and building a market-leading team
OptimizeRx (OPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
The availability of Micro-Neighborhood ® Targeting on the Company's Dynamic Audience Activation Platform meets the demand of life sciences marketers by synchronizing consumer and physician marketing
OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.07 per share. This compares to loss of $0.01 per share a year ago.
WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Thursday, August 8, 2024, at 4:30 p.m. Eastern Time to discuss its results for the second quarter period ended June 30, 2024. The financial results will be issued in a press release prior to the call.
The Company's AI-guided predictive targeting platform delivered three times the return in half the time of the traditional trigger-based program The Company's AI-guided predictive targeting platform delivered three times the return in half the time of the traditional trigger-based program